Background: Diabetes mellitus (DM) is becoming increasingly common in developing countries and is of major concern in the Middle East and North Africa (MENA). Since at least 30% of diabetic patients may develop painful diabetic peripheral neuropathy (pDPN) within their lifetime, there is an urgent need to increase awareness of the condition among physicians in the region.
Introduction
Once considered a 'disease of affluence', diabetes mellitus (DM) is becoming increasingly common in developing countries and is of major concern in the Middle East and North Africa.(1) Complications of diabetes include cardiovascular disease, nephropathy and retinopathy, but the most commonly encountered complication is diabetic peripheral neuropathy (DPN), (2) and it is estimated that approximately 30% of diabetic patients have painful diabetic peripheral neuropathy (pDPN).(2-6) Clinically, DPN is a diagnosis of exclusion, defined as "the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after the exclusion of other causes".(7) pDPN has a significant negative impact on quality of life by reducing patients' mobility and ability to perform everyday tasks, increasing the risk of foot ulcers and amputation, disturbing sleep and causing psychological distress. (3, 8) pDPN is widely under-diagnosed and often poorly treated. A survey conducted by the American Diabetes Association in 2005 found that up to 75% of patients who experienced pDPN symptoms were not diagnosed and that 56% of these patients were not even aware of the condition. (5) Other studies have also shown that patients who do receive treatment are often dissatisfied with the outcomes. (6, 9) The few studies of pDPN that have been conducted in Middle Eastern and North African countries suggest prevalence ranges from 22-65%, reflecting different populations and methods of diagnosing this condition, but may also indicate true differences from the expected prevalence of approximately 30%. (1, (10) (11) (12) The present review and clinical guidelines aim to increase awareness of pDPN among physicians in the Middle East and North Africa as well as to provide practical consensus recommendations to facilitate the diagnosis and management of pDPN in the region.
Materials and Methods
A panel of seven family medicine physicians from the Middle East and North Africa, together with Professor Rayaz A. Malik from Weill Cornell Medicine in Doha, Qatar and NY, USA, was convened in Dubai, United Arab Emirates, on 17 October 2015. The panel members had extensive clinical and research expertise in the diagnosis and management of pDPN in the general practice setting, while Professor Malik, who is a member of the writing group for the 2016 American Diabetes Association consensus statement on diabetic neuropathy, was an advisor to the panel. The key objectives of the meeting were to gain a better understanding of the most pressing challenges facing family medicine practitioners in the region regarding the management of pDPN in their day-to-day clinical practice and to develop consensus recommendations to optimize diagnosis and treatment.
The panel discussed 6 pertinent themes: 1) the current state of awareness of pDPN among physicians in the region, 2) key features of patient presentations with pDPN, 3) issues and challenges facing physicians with respect to screening for neuropathic pain, 4) goals and routine management strategies, 5) problems with initiating and maintaining treatment, and 6) methods for optimizing the patient-physician relationship based on evidence-based guidelines on the screening, diagnosis and management of pDPN. (1, 10, 13) Recommendations Epidemiology Estimates of the prevalence of pDPN vary widely in the region due to a paucity of data. Moreover, current prevalence rates may be underestimated as patients often do not approach their physicians with symptoms of neuropathic pain and many remain undiagnosed. (8) The worldwide prevalence of pDPN among patients with DM is estimated to be around 30%, however in the Middle East and North Africa this ranges from 22.5-65% (Figure 1 ). (1, 10, 13) Of note, most data have been gathered from patients in secondary and tertiary care centers and studies in primary care are required to establish the true prevalence of pDPN. Severe pain may significantly interfere with a patient's ability to exercise or walk, limit general activities of daily living, and alter sleep patterns as symptoms are often most intense at night (5, 14, 15) . Indeed, one study reported that patients with pDPN who suffered from severe pain were willing to trade nearly a full day of their lives in order to avoid 1 additional hour of pain. (15) In addition, they also reported feeling approximately (21) years older than their actual age. (15) The combination of intense pain, sleep disturbance, poor mobility, and inability to perform general activities of daily living imposes a heavy toll on patients, which are strongly associated with mood disorders such as depression and anxiety ( Figure 2) . (16) Whilst a previous study of 200 Emirati subjects with diabetes demonstrated an above average QoL score, this was significantly reduced in those with at least one complication affecting the 'foot', heart, eye or kidney.(17)
Etiology and risk factors
The exact etiology of pDPN is unknown and may be attributable to a combination of chronic hyperglycemia and cardiovascular risk factors such as dyslipidaemia and hypertension. (18) The Diabetes Control and Complications Trial (DCCT) and its follow-up study, the Epidemiology of Diabetes Interventions and Complications (EDIC) trial, showed that intensive glycemic control can delay the development and progression of diabetic neuropathy in patients with type 1 DM (T1DM). (19, 20) However, patients with type 2 DM (T2DM) do not seem to benefit from intensive glycemic control as per a Cochrane meta-analysis and several large clinical trials. (4, 21, 22) Lipid levels, blood pressure, inflammation, insulin resistance, oxidative stress, vitamin D deficiency, height, cigarette smoking, and alcohol consumption have all been related to pDPN in various studies. (2, 10, (22) (23) (24) Epidemiological analyses suggest that the following are significant risk factors for pDPN(25):
• long-standing diabetes of >10 years' duration • age >65 years • body mass index (BMI) >30
• female sex
Pathophysiology
The exact mechanisms underlying pDPN remain unclear, but both the peripheral and central nervous system are thought to be involved. Painful sensations can arise from damage to the A and C nerve fibers. Lesions of the peripheral nerves can increase their excitability, a phenomenon known as peripheral sensitization. This occurs via increased or altered sodium channel expression and function, which is associated with spontaneous painful discharges and reduced thresholds for activation leading to neuropathic pain. (26) Increased calcium channel expression also encourages the release of excitatory neurotransmitters such as glutamate and substance P, and can increase the excitability of neurons in the spinal cord (central sensitization) (Figure 3 ). (23, 27) Efferent nerve fibers that descend from the brain to the dorsal horn of the spinal cord have a powerful inhibitory effect on pain signals sent via the afferent fibres; their function is reliant on neurotransmitters such as y-aminobutyric acid (GABA), serotonin, and noradrenalin. Dysfunction of these pathways can also result in central sensitization. (27) Clinical presentation Patients with pDPN tend to describe their symptoms using similar terms and most describe either numbness or a tingling, electric shock-like, burning, shooting or stabbing pain in their feet or lower legs due to the involvement of the small sensory nerve fibers (Table 1) 
Diagnosis and evaluation
A comprehensive physical examination should be performed when a patient with diabetes presents with neuropathic pain. A careful clinical history should be undertaken as the differential diagnoses are many and varied, and diagnosis may be challenging ( Table 2 ).
The first step in assessing a patient is to determine whether there is any evidence of neuropathic pain. Neuropathic pain can be distinguished from nociceptive pain by using a screening tool and performing a thorough clinical examination (Table 3) . 
O R I G I N A L CO N T R I B U T I O N / C L I N I C A L I N V E S T I G AT I O N

Screening tools
It is recommended that all patients with metabolic syndrome/impaired glucose tolerance and Type 1/2 diabetes should be screened for neuropathic pain at least annually. A number of different screening tools are available that can aid with differentiating neuropathic and nociceptive pain including the Neuropathic Pain Questionnaire, the 
Clinical Assessments
Patients with pDPN present initially with pain in the feet and physicians are thus advised to remove a patient's shoes and socks to undertake a thorough clinical examination of the patient's feet. Tests include not only the three tests performed as part of the DN4 (testing for touch, pinprick, and allodynia), but also a more careful analysis of the patient's description of their pain. Traditionally, a monofilament has been used for assessing neuropathy; however, this is only useful for evaluating advanced neuropathy and for identifying patients at high risk of foot ulceration. It should therefore not be used to identify neuropathy as it will often be normal despite significant small fiber neuropathy.
The 3L (listen, look, locate) approach is recommended for identifying signs and symptoms of neuropathic pain (27) :
• Listen to the patient's verbal description of their pain and note any mention of non-painful symptoms that are experienced in the same area as the pain.
• Look for any sensory abnormalities such as pain felt upon touching the sensitive area and note any unusually warm or cold regions and differences in color or texture relative to a non-painful adjacent site.
• Locate the region of pain and document its position using a pain drawing, which can be created by the patient or the physician. Make a note of any abnormal sensations on the drawing. Increasing patient awareness is important for encouraging patients to self-report painful symptoms. Patients may not volunteer this information and it is recommended that physicians ensure that all at-risk patients are aware of the possibility of developing pDPN and of the symptoms they should look out for. It is also important to note that approximately 10-15% of patients with diabetes who experience neuropathic symptoms will have a neuropathy from another cause that may be treatable. 
Contemporary Management
There is currently no cure for pDPN and treatment is challenging as many patients do not experience sufficient pain relief. (28, 31) In this context, combination pain relief regimens may be more effective than the traditional approach of trialing and discontinuing a single agent if this fails to provide sufficient relief. (31) Treatment goals are focused on preventing the development or progression of DPN through an improvement in glycaemic control and vascular risk factors and educating patients as to how best to address their symptoms, employing pharmacologic and/or nonpharmacologic agents to help manage neuropathic pain to improve the patient's QoL. Other options include opioid analgesics (Table 5) . (31, 32) Other therapies such as topical nitrate, vitamin D and alpha lipoic acid, (33, 34) as well as non-pharmacological therapy such as acupuncture, and transcutaneous electrical nerve stimulation may also have a place in treating patients with pDPN. Vitamin B is frequently used in pDPN management in the MENA region, however, there are limited data in randomized trials testing the efficacy of vitamin B for treating peripheral neuropathy and meta-analyses have reported inconclusive evidence for its role in therapy. (35) Practice points: Pharmacologic therapy of pDPN • Use GABA analogs (pregabalin or gabapentin), tricyclic antidepressants (TCAs) and serotoninnorepinephrine reuptake inhibitors (SNRIs) first-line • Consider combining pregabalin or gabapentin with SNRIs or TCAs • Opioid analgesics can be given for second-line use Table 4 : Global first-and second-line recommendations for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (31, 32) O
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Patient counseling
Patients should be given clear, specific information on how to use their medications as well as counseling on expectation of the response to therapy, as an expected response may be 50% at best whilst a 30% reduction in pain is considered clinically meaningful. Patients may be disappointed if they expect complete resolution of their painful symptoms.
Physicians should clarify that the agents prescribed are used for a specific purpose and that many have multiple indications: TCAs for example are prescribed for their effect on neuropathic pain not because of their antidepressant effects and this should be made clear to patients. In addition, patients should also be educated about the side effects of different medications especially when prescribed in high doses and both benefits and disadvantages should be openly discussed with the patient, to ensure compliance.
It is also important to follow-up on treatment to ensure that the prescribed medication is having the intended effect; if not, the dose should be increased or an alternative be prescribed. A simple 11-point pain scale can be useful for distinguishing 'before' and 'after' pain scores to help determine the effectiveness of the prescribed treatment.
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-c l av u l a n i c a c i d a n d Once neuropathy has been diagnosed, causes other than pDPN should be excluded. Affected patients can be managed according to international treatment recommendations for pDPN. Anticonvulsants (such as pregabalin and gabapentin), SNRIs and TCAs are recommended for first-line treatment. Patients should be closely followedup and those with inadequate pain relief should be offered an alternative first-line agent that has a different mechanism of action, or combination therapy. Secondline agents should be reserved for patients who suffer more severe pain and who are unable to obtain adequate relief from first-line agents either alone or in combination.
